Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

ClinicalTrials.gov ID: NCT02612922

Public ClinicalTrials.gov record NCT02612922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of acute uncomplicated influenza.

Study identification

NCT ID
NCT02612922
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Romark Laboratories L.C.
Industry
Enrollment
325 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2015
Primary completion
Sep 3, 2016
Completion
Sep 3, 2016
Last update posted
Apr 3, 2018

2015 – 2016

United States locations

U.S. sites
17
U.S. states
8
U.S. cities
17
Facility City State ZIP Site status
Influence Study Site Hot Springs Arkansas 71913
Influence Study Site Anaheim California 92805
Influence Study Site Fresno California 93702
Influence Study Site Lomita California 90717
Influence Study Site Kissimmee Florida 34744
Influence Study Site Lauderdale Lakes Florida 33319
Influence Study Site Saint Cloud Florida 34769
Influence Study Site Columbus Georgia 31904
Influence Study Site Savannah Georgia 31401
Influence Study Site Lansdale Pennsylvania 19446
Influence Study Site Rapid City South Dakota 57702
Influence Study Site Jackson Tennessee 38305
Influence Study Site Austin Texas 78735
Influence Study Site Houston Texas 77058
Influence Study Site Pharr Texas 78577
Influence Study Site Plano Texas 75024
Influence Study Site Waco Texas 76710

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02612922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2018 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02612922 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →